<?xml version="1.0" encoding="UTF-8"?>
<p id="par0135">Furthermore, it is necessary to pay special attention to the immunomodulatory effect of SSHT. In an experimental study using a cyclophosphamide-induced immunosuppression animal model,
 <xref rid="bib0290" ref-type="bibr">
  <sup>58</sup>
 </xref> SSHT was shown to exert an immunomodulatory effect that increases lymphocytes only in the immunosuppressive model (and is invalid in the normal animal model). In an observational study of 21 patients with COVID-19,
 <xref rid="bib0295" ref-type="bibr">
  <sup>59</sup>
 </xref> early lymphocyte degradation was observed to be a characteristic observation in the patients, suggesting that early lymphocyte degradation would have diagnostic value. Considering these serologic abnormalities associated with early COVID-19 and the immunomodulatory effect of SSHT, it is possible that the use of SSHT in the early to mid-term stages of the disease could be helpful (
 <xref rid="tbl0015" ref-type="table">Table 3</xref>).
</p>
